Literature DB >> 8075860

Comparison of the ability of nicardipine, theophylline and zaprinast to restore cardiovascular haemodynamics following inhibition of nitric oxide synthesis.

N A Herity1, J D Allen, B Silke, A A Adgey.   

Abstract

1. The use of pharmacological inhibitors of nitric oxide (NO) synthesis to treat patients with septic shock is limited by the observation that they cause a fall in cardiac output in some subjects. The aim of this work was to investigate this fall and to test whether it was reversible by subsequent administration of nicardipine, theophylline or the cyclic GMP-selective phosphodiesterase inhibitor, zaprinast (M&B 22948). 2. In pentobarbitone-anaesthetized pigs, haemodynamic indices were measured before and after intravenous administration of NG-nitro-L-arginine methyl ester (L-NAME) in a dose-response protocol (0.2-20 mg kg-1; n = 6) and as a single bolus of 10 mg kg-1 either alone or followed by increasing doses of nicardipine, theophylline or zaprinast (n = 8 in each group). 3. L-NAME caused a dose-dependent rise in systemic vascular resistance and mean systemic arterial pressure and a dose-dependent fall in cardiac output. A single bolus of L-NAME (10 mg kg-1) produced these effects within 15 min. 4. Subsequent administration of nicardipine (0.05-0.2 mg kg-1) caused complete reversal of systemic vasoconstriction and hypertension and in doing so completely restored cardiac output. Theophylline (7.5-10 mg kg-1) partially reversed the rise in systemic vascular resistance and partially restored cardiac output but the effect was small compared to that of nicardipine. Zaprinast (1-5 mg kg-1) had no significant effect on any of these variables. 5. These results suggest that reduced cardiac output following inhibition of NO synthesis is an effect of increased afterload on the heart and is reversible by nicardipine and to a lesser extent by theophylline.These findings may have potential value for those using NO synthase inhibitors to treat patients with septic shock.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8075860      PMCID: PMC1910380          DOI: 10.1111/j.1476-5381.1994.tb13089.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  34 in total

1.  Induction and potential biological relevance of a Ca(2+)-independent nitric oxide synthase in the myocardium.

Authors:  R Schulz; E Nava; S Moncada
Journal:  Br J Pharmacol       Date:  1992-03       Impact factor: 8.739

2.  Myocardial and circulatory effects of E. coli endotoxin; modification of responses to catecholamines.

Authors:  J R Parratt
Journal:  Br J Pharmacol       Date:  1973-01       Impact factor: 8.739

3.  Effects of anesthesia on baroreflex control of heart rate in man.

Authors:  J D Bristow; C Prys-Roberts; A Fisher; T G Pickering; P Sleight
Journal:  Anesthesiology       Date:  1969-11       Impact factor: 7.892

4.  Cardiovascular response to increasing theophylline concentrations.

Authors:  R I Ogilvie; P G Fernandez; F Winsberg
Journal:  Eur J Clin Pharmacol       Date:  1977-12-28       Impact factor: 2.953

5.  The influence of atropine and atenolol on the cardiac haemodynamic effects of NG-nitro-L-arginine methyl ester in conscious, Long Evans rats.

Authors:  R E Widdop; S M Gardiner; P A Kemp; T Bennett
Journal:  Br J Pharmacol       Date:  1992-03       Impact factor: 8.739

6.  Regional and cardiac haemodynamic effects of NG, NG,dimethyl-L-arginine and their reversibility by vasodilators in conscious rats.

Authors:  S M Gardiner; P A Kemp; T Bennett; R M Palmer; S Moncada
Journal:  Br J Pharmacol       Date:  1993-12       Impact factor: 8.739

7.  The pharmacological activity of nitroxyl: a potent vasodilator with activity similar to nitric oxide and/or endothelium-derived relaxing factor.

Authors:  J M Fukuto; K Chiang; R Hszieh; P Wong; G Chaudhuri
Journal:  J Pharmacol Exp Ther       Date:  1992-11       Impact factor: 4.030

8.  Nitric oxide production within cardiac myocytes reduces their contractility in endotoxemia.

Authors:  A J Brady; P A Poole-Wilson; S E Harding; J B Warren
Journal:  Am J Physiol       Date:  1992-12

9.  Role of basal release of nitric oxide on coronary flow and mechanical performance of the isolated rat heart.

Authors:  M Amrani; J O'Shea; N J Allen; S E Harding; J Jayakumar; J R Pepper; S Moncada; M H Yacoub
Journal:  J Physiol       Date:  1992-10       Impact factor: 5.182

10.  Nitric oxide synthase activities in human myocardium.

Authors:  A J de Belder; M W Radomski; H J Why; P J Richardson; C A Bucknall; E Salas; J F Martin; S Moncada
Journal:  Lancet       Date:  1993-01-09       Impact factor: 79.321

View more
  3 in total

1.  Inhaled nitric oxide in combination with volume resuscitation refines a porcine model of endotoxic shock.

Authors:  N A Herity; J D Allen; B Silke; A A Adgey
Journal:  Ir J Med Sci       Date:  2001 Jul-Sep       Impact factor: 1.568

2.  Increase by NG-nitro-L-arginine methyl ester (L-NAME) of resistance to venous return in rats.

Authors:  Y X Wang; S L Lim; C C Pang
Journal:  Br J Pharmacol       Date:  1995-04       Impact factor: 8.739

3.  Hemodynamic Effects of Cardiovascular Medications in a Normovolemic and Hemorrhaged Yorkshire-cross Swine Model.

Authors:  Jacob H Cole; Scott B Hughey; Phillip G Geiger; Kamala J Rapp-Santos; Gregory J Booth
Journal:  Comp Med       Date:  2021-12-07       Impact factor: 1.565

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.